CN1400004A - Chinese medicine preparation for curing chronic conjunctivitis - Google Patents
Chinese medicine preparation for curing chronic conjunctivitis Download PDFInfo
- Publication number
- CN1400004A CN1400004A CN02131250A CN02131250A CN1400004A CN 1400004 A CN1400004 A CN 1400004A CN 02131250 A CN02131250 A CN 02131250A CN 02131250 A CN02131250 A CN 02131250A CN 1400004 A CN1400004 A CN 1400004A
- Authority
- CN
- China
- Prior art keywords
- preparation
- flos
- eye
- conjunctivitis
- borneolum syntheticum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010010741 Conjunctivitis Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 201000005547 chronic conjunctivitis Diseases 0.000 title claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 17
- 241001113925 Buddleja Species 0.000 claims abstract description 3
- 241000245240 Lonicera Species 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000003889 eye drop Substances 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 20
- 244000293323 Cosmos caudatus Species 0.000 claims description 17
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 9
- 210000000744 eyelid Anatomy 0.000 claims description 8
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 241000201295 Euphrasia Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 230000001139 anti-pruritic effect Effects 0.000 claims description 4
- 239000003908 antipruritic agent Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 235000014435 Mentha Nutrition 0.000 claims description 2
- 241001072983 Mentha Species 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 229960003415 propylparaben Drugs 0.000 claims 2
- 239000000463 material Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract 1
- 244000246386 Mentha pulegium Species 0.000 abstract 1
- 235000016257 Mentha pulegium Nutrition 0.000 abstract 1
- 235000004357 Mentha x piperita Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000001050 hortel pimenta Nutrition 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 33
- 230000000694 effects Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 241000475481 Nebula Species 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 241000186216 Corynebacterium Species 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 241001312524 Streptococcus viridans Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940097572 chloromycetin Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 2
- 241000150100 Margo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- CGSVCNBINHWWFW-UHFFFAOYSA-M dimethyl-(2-phenoxyethyl)-(thiophen-2-ylmethyl)azanium;chloride Chemical compound [Cl-].C=1C=CSC=1C[N+](C)(C)CCOC1=CC=CC=C1 CGSVCNBINHWWFW-UHFFFAOYSA-M 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 241000167686 Reichardia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010067130 Spastic diplegia Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a Chinese medicine eye preparation for curing chronic conjunctivitis. It is made of the Chinese medicinal materials of lonicera flower, buddleia flower, wild chrysanthemum flower, peppermint, pearl and borneol as raw material.
Description
Technical field:
The present invention relates to a kind of Chinese medicine ophthalmic preparation for the treatment of the chronic eye conjunctivitis, said preparation is processed into by raw material of Chinese medicine such as Flos Lonicerae, Flos Buddlejae, Flos Chrysanthemi Indici, Herba Menthae, Margarita, Borneolum Syntheticums.
Background technology:
Eye conjunctivitis is that infectiousness and epidemic eyes are rubescent to having, conjunctival congestion (or hemorrhage), the acute bacterial of secretions increase or the general designation of viral or anaphylaxis conjunctivitis for people.
According to the argumentation of the traditional Chinese medical science, the cause of disease of primary disease has three kinds:
1. mistake was supported after affection due to external wind and heat was suffered from the order disease, and the surplus heresy of wind heat is not most, and heresy is tied with the stasis of blood, the retardance venation, and legendary small dragon with horns is red in length and breadth and form white gossamer arteries and veins, and (" Standards of Diagnosis and Treatment ") for a long time and not heal.
2. the liver interior-heat is stifling, fills to send out to cause the red puckery and pain (" General Treatise on the Cause and Symptoms of Diseases ") of order heat in order.
3. liver has heat, heat stagnation arteries and veins resistance, and the network blood stasis that stagnates, body fluid can not sending nutrient upward to eye, so dry and astringent and swelling pain (" holy Ji is always helped ") in the order.
Surplus evil delay of primary disease exopathogenic factor wind heat, interiorly to steam in order on hot and suffocating by internal organs, its characteristics are as follows: the cause of disease: based on wind and heat, the liquid deficiency of foster order is next.
Sick position: pathological changes is at upper and lower born of the same parents' eyelid and white of the eye.
Relevant internal organs: at lung, liver and taste.Lung governing qi, white of the eye belongs to lung, is turbine.The liver being in charge of the eyes, and The eye is the body opening of the liver, and it is the meat wheel that taste master muscle, last lower eyelid eyelid belong to taste.
Pathogenesis: the venation that 1. the surplus heresy of wind heat is not most, the visitor hinders gum eyelid and white of the eye.
2. lung in the internal organs, liver, taste are hot and suffocating, steam the order key that burns.
3. blockage of the vessel, cloudy liquid can not be gone up profit, or impairment of YIN with the passing of time, and order loses profit and supports.
Wind heat visitor resistance can the anfractuosity legendary small dragon with horns be red in length and breadth to born of the same parents' eyelid flesh noodles and white of the eye venation; The visitor of ailment said due to cold or exposure institute is then from itching; Pathogenic heat is steamed and then given birth to gum, and is scorching hot not well in the order; The heat stagnation network cloudy liquid that stagnates can not be gone up honor or impairment of YIN dryness and uneasy feeling of the eye's pain then with the passing of time.Since primary disease mostly be waste heat to the greatest extent due to, so it is light to form evil little disease, the characteristics of the slow delay of gesture, clinical manifestation is that sign is lighter, symptom is attached most importance to, very the person itches puckery pain unbearably, can not watching for a long time, influence working and learning.
The treatment eye conjunctivitis uses antibacterials and Claritin more at present, but the chronic eye conjunctivitis there is not good active drug, Chinese patent disclosed some methods of using the treatment by Chinese herbs eye conjunctivitis, as: CN1207322, CN1132627, CN1108556, CN1100953, CN89105757.9, the prescription of these patents all do not have success be used for clinical, and the recipe ingredient complexity, expensive raw material price.
Summary of the invention:
The invention provides a kind of new Chinese medicine preparation, this prescription is used to prepare the Chinese medicine ophthalmic preparation of treatment chronic conjunctivitis.
This prescription composed as follows:
Flos Lonicerae, Flos Buddlejae, Flos Chrysanthemi Indici, Herba Menthae, Margarita, Borneolum Syntheticum
The function of this prescription with curing mainly is: cleaning heat and expelling wind, to move back red antipruriticly, and yin nourishing makes eye bright.Be used for eyelid and white fine blood vessel anfractuosity due to the wind heat visitor network, or blood vessel is indistinct, eye is scratchy dry and astringent, and the mill pain is scorching hot, or eye secretion, being unable to see for a long time, watching for a long time ache (chronic conjunctivitis) are arranged.
According to theory of Chinese medical science, primary disease should not use clearing up internal heat by using drugs of bitter in taste and cold in nature aspect rule of treatment method of treatment, the hot heavy prescription that looses and dispel the wind, and should select wind and heat dispersing for use, move back red antipruritic, the light diaphoretic prescription of yin nourishing profit order.Wind reduces phlegm and internal heat and moves back then strongly fragrant separating, and stagnates to lead to, red then move back, itch can end, gum can disappear.Cloudy liquid is given birth to, then puckery the profit, and pain is from disappearing, and order can be bright.
Prescription of the present invention is pressed the monarch principles of formulating prescriptions and is determined
Flos Lonicerae property is sweet cold in the side, goes into lung stomach large intestine channel, and heat-clearing and toxic substances removing is arranged, the merit of light a surname evacuation.Internal energy clear internal organs lung stomach is hot and suffocating, the heresy of external enwergy dispelling wind and heat pathogens.Wind heat is clear, and stasis is loose, and then white of the eye, the red Chi Qiumai of born of the same parents' eyelid can move back, and the puckery twinge of itching can disappear.Be monarch drug in the side.
Flos Chrysanthemi Indici in the side, toil is slightly cold, and goes into lung liver two warps, and heat-clearing and toxic substances removing has the conjunctival congestion of moving back, goes the merit of pruritus.Flos Buddlejae is sweet to be slightly cold, the duty that go into Liver Channel, tool liver heat removing nebula removing, makes eye bright, and the two and monarch drug are harmonious, and are aided with liver heat removing, lung, move back red nebula, and be antipruritic puckery, bright eyes.Herba Menthae is pungent in flavor and cool in property, goes into the liver lung meridian, and soothing the liver stagnating arranged especially, and the merit that removes stagnant heat is with the merit deficiency of auxilliary Flos Lonicerae evacuation.Three's phase 5 is a ministerial drug.
Margarita in the side, sweet salty-cold, go into conscience two warps, there is liver heat removing to remove nebula, the merit that heart-fire, yin nourishing make eye bright falls in the town.For ophthalmology external commonly used one of is put drops in one's eyes." Kaibao Bencao " assists monarch drug to move back blood vessel with this product " some order, the skin cataracta of dispelling film ", removes the nebula film, and be nourshing Yin and drynsessmoistening prescription, is adjuvant drug.
Borneolum Syntheticum in the side arduous is slightly cold, GUIXIN, spleen, lung meridian.Its nature and flavor delicate fragrance is that hundred medicines are earlier, has logical all keys, and conjunctival congestion skin nebula is gone in the stagnated fire of loosing, and the merit that makes eye bright not only be the key medicine of eye dripping, more can guide the current order key of his medicine, work in coordination with and control the order disease.Amplification on Canon of Materia Medica is pointed out this product " a little less than the gesture of walking alone then, assistant makes then meritorious ", and its messenger drug effect in this prescription also is described.
More than six medicines combinations, the tool cleaning heat and expelling wind moves back red antipruritic merit altogether.To belonging to the wind heat visitor resistance or the disease of impairment of YIN with the passing of time in the disease such as conjunctival congestion, chronic conjunctivitis dry astringent eye, xerosis conjunctivitis for many years, particularly suitable.
The weight proportion of each component was as follows during prescription of the present invention was formed:
Flos Lonicerae 50-150 part, Flos Buddlejae 50-150 part, Flos Chrysanthemi Indici 50-150 part, Herba Menthae 40-120 part, Margarita 2.5-7.5 part, Borneolum Syntheticum 0.5-1.5 part
The proportioning of preferred each component was as follows during prescription of the present invention was formed:
Flos Lonicerae 75-125 part, Flos Buddlejae 75-125 part, Flos Chrysanthemi Indici 75-125 part, Herba Menthae 60-100 part, Margarita 3-7 part, Borneolum Syntheticum 0.75-1.25 part
Most preferred proportioning is as follows:
100 parts of Flos Loniceraes, 100 parts of Flos Buddlejaes, 100 parts of Flos Chrysanthemi Indicis, 80 parts of Herba Menthaes, 5 parts of Margaritas, 1 part of Borneolum Syntheticum
Preparation of the present invention is an ophthalmic preparation, and preferred preparation is solution, eye drop, applies eye agent, eye unguentum, collyrium that most preferred preparation is an eye drop.
The preparation method of the ophthalmic preparation by above-mentioned formulated of the present invention is as follows:
A. get Flos Buddlejae, Flos Chrysanthemi Indici and Herba Menthae three flavor medicines, add water, steam distillation is collected distillate;
B. the Flos Lonicerae extracting in water filters, and concentrates, and precipitate with ethanol filters, and concentrates, and adds water;
C. crushing pearl adds water furnishing pasty state, adds hydrochloric acid hydrolysis and makes moltenly, leaves standstill, filter, and filtering residue reuse hydrochloric acid hydrolysis, hydrolyzed solution filters, and merges hydrolyzed solution twice, and acid is driven in heating, transfers PH closely neutral, concentrates drying;
D. Borneolum Syntheticum adds water and makes moltenly, adds the Margarita powder of step c, the Flos Lonicerae extractive solution of step b, and the distillate of three medicines such as the Flos Buddlejae of step a, the medicine acceptable carrier adds water, filters sterilization.
Preferable methods is as follows:
Above Six-element is got Flos Buddlejae, Flos Chrysanthemi Indici and Herba Menthae three flavor medicines, adding distil water, and steam distillation is collected (armaticity) distillate, and device is stored in addition; Flos Lonicerae decocts with water extraction, and decoction liquor is filtered, and filtrate merges, be concentrated into 1: 1 (medicinal liquid: concentration medical material), add ethanol precipitation, filter, concentrate, adding distil water, it is standby to sterilize; Margarita powder is broken into powder; Add an amount of furnishing pasty state of water, add concentrated hydrochloric acid hydrolysis and make moltenly, standing demix filters, the hydrolysis of filtering residue reuse hydrochloric acid reflux, and hydrolyzed solution filters, and merges hydrolyzed solution twice, and heating in water bath drives acid, transfers PH closely neutral again, concentrates drying for standby; Borneolum Syntheticum adds water and grinds and to make moltenly, is sequentially added into the armaticity distillate of three medicines such as soluble pearl powder, Flos Lonicerae extractive solution, Flos Buddlejae and sodium chloride then, methyl parahydroxybenzoate, propyl ester mixture, add water recently distilled at last, transfer PH to 5.5-6.5, mix homogeneously.Cold preservation filters, fine straining again, and the filtrate sterilization, packing under the aseptic condition, packing is promptly.
Medicament for the eyes of the present invention, using method are that every day three times, each every eyes 2-3 drips.
Pharmaceutical preparation of the present invention shows good beneficial effect through zoopery, below is experiment content.
One. eye drop of the present invention is to the influence of rabbit conjunctivitis
1. eye drop of the present invention is to the influence of rabbit infective conjunctivitis
Method: the reference literature correct is carried out, the rabbit conjunctival sac antibacterial culturing of drawing materials, and bacterium inspection feminine gender experimentizes.After smearing palpebral conjunctiva 10 times with aseptic cotton carrier, draw the scar of 5mm * 6mm "+" at upper tarsal conjunctiva with the aseptic operation knife back, the degree of depth is broken and be not advisable thoroughly (not hindering tarsus) with epithelial layer, change carry eyelid eyelid pulled into cup-shaped after, in conjunctival sac, splash into bacterium liquid (golden Portugal bacterium 5 * 10
9Cfu/ml) 4 (about 0.2ml) keeps resetting after 30 seconds.After 24 hours, draw materials and do the bacterium inspection, choosing is infected the conjunctivitis winner and is used for test, drips medicine (with the medicine of embodiment 1 method preparation) treatment, each 1 (being equivalent to 0.05Ml) every day 3 times, inflammatory activity for three days on end.Adopt non-parametric ranked data statistics Ridit to analyze
[3]Method is carried out statistical procedures.
Table 1 curative effect judging standard:
0 minute 1 minute 2 minutes 3 sub-item fissura palpebraes of rank normal little obviously little margo palpebrae of not opening eyes of opening eyes is normally wet, the hyperemia of pieces shape, the edema wrinkle Zhe secretions that turns up does not have a small amount of conjunctival sac margo palpebrae adhesion of corner of the eyes portion
The secretion papebral conjunctiva does not have the congested bulbar conjunctiva of slight moderate severe and does not have the congested bulbar conjunctiva of slight moderate severe and do not have the normal little cloud point of the transparent little protuberance cornea of bulge blister projection oedema and dye and infiltrate the pannus pupil and normally dwindle
Every inspection index meter 0,1,2,3 minute;
The comprehensive criterion of curative effect:
0-0.5 be divided into healing; 1-1.5 be divided into produce effects; 1.5-2.5 be divided into improvement; 2.5 more than dividing is invalid.
Table 2 eye drop of the present invention is to observation of curative effect group model group eye drop chloromycetin solution of the present invention eye number (only) 10 10 10 10 dosage (mg/kg) of rabbit infective conjunctivitis--and 5.79 11.58 0.38
Cure--543
Produce effects 1365 administrations
Take a turn for the better 32----three days
Invalid 6----2
Effective percentage (%) 10 80* 100** 80*
Annotate: effective percentage=healing+produce effects:
*P＜0.05，**P＜0.01；
All compare (as follows) with model group.
As a result table 2 as seen, it only is 10% that model group gives the 3rd day obvious effective rate of normal saline, large and small two the dosage group effective percentage of eye drop of the present invention are respectively 100% and 80%, with model group highly significant and significant difference are arranged relatively respectively.Chloromycetin eyedrops also has similar effect.2. eye drop of the present invention is to the influence of rabbit chronic conjunctivitis
Use the medicament for the eyes of embodiment 1 method preparation
Method: rabbit chronic conjunctivitis model is at present domestic not to appear in the newspapers as yet, and we have set up rabbit chronic conjunctivitis model with the method for sunkening cord.After Animal Anesthesia, sunkening cord under bulbar conjunctiva elongation limbus of sclera 2mm place row bulbar conjunctiva, (scope: 180 ° of tops), the end of a thread does not expose.Drip the medicine treatment after 24 hours, every day 3 times, continuous 2 weeks.
Curative effect is checked: by torch bore hole and the fluorescent staining slit lamp examination day by day of 2-3 people's double-blind method.Curative effect judging standard is with infectious conjunctivitis.
Table 3 eye drop of the present invention is to observation of curative effect group model group eye drop chloromycetin solution of the present invention eye number (only) 11 11 11 11 dosage (mg/kg) NS 5.79 11.58 0.38 of rabbit chronic conjunctivitis
Cure--------
Produce effects--5 11 5 administrations
Take a turn for the better 22--11 weeks
Invalid 94--5
Effective percentage (%)--45.5 100** 45.5*
Cure--79--
Produce effects 3428 administrations
Take a turn for the better 22 weeks of 7----
Invalid 1----1
Effective percentage (%) 18.2 100** 100** 72.7* results model groups gave behind the normal saline for 1 week no obvious therapeutic effect, only two eyes take a turn for the better, the heavy dose of group of eye drop of the present invention 100% produce effects, small dose group also has 45.5% produce effects; In two weeks of successive administration, small dose group 100% is effective, and heavy dose of group cures 81.2%, and small dose group cures 63.6%, and the effective percentage of positive control drug also obviously improves, and reaches 72.7%.Point out eye drop of the present invention that chronic conjunctivitis is had the obvious treatment effect.Two. the antiinflammatory action method of eye drop of the present invention adopts Mus ear swelling method according to document
[2]Carry out, with male mice with 100% dimethylbenzene (0.02ml/ only), be applied to ear back, an animal left side, be coated with eye drop of the present invention and positive drug after half an hour respectively,, the dislocation of mice cervical vertebra caused death every 4 hours, cut two ears from the auricle baseline, lay round auricle at same position respectively with 7mm diameter card punch,, deduct the auris dextra sheet with every Mus left side auricle weight and heavily be swelling degree (adopting the F-Q method of inspection) with ten thousand/scales/electronic balance weighing.
Table 4 eye drop of the present invention is to the therapeutical effect of mice ear
The dosage Mus is counted ear swelling degree suppression ratio
(mg/kg) (only) (mg) (%) P value group matched group NS 15 4.3 ± 1.8 eye drops 17.37 15 1.6 ± 1.1 62.8＜0.01 of the present invention
34.74 15 3.2 ± 2.6 25.6 pairs of chlorine eye liquid 0.45 15 2.7 ± 1.5 37.2＜0.05 eye drop high dose group xylol induced mice dropsy of ear of the present invention as a result have significant inhibitory effect, its suppression ratio can reach 62.8%, small dose group also has certain inhibitory action, but compares there was no significant difference with matched group; Positive control drug also has the obvious suppression effect.Three. the bacteriostatic test of eye drop of the present invention is by medicinal liquid doubling dilution in vitro: with the continuous doubling dilution of caseinhydrolysate (MH) meat soup, dilution factor is followed successively by stock solution, 1: 2,1: 4,1: 8 with eye drop of the present invention (38.6mg/ml), and terminating bacterium amount is 10
2With 10
3Cfu/ml, contrast bacterium method is identical.In 35 ℃ cultivate 24 hours after observed result.1 minimum inhibitory concentration: with naked eyes as seen the minimum dilution tube of bacteria growing not being arranged is minimum inhibitory concentration.2 minimum bactericidal concentrations: not seeing the transferred species of the meat soup in vitro blood plate of bacterial growth after will cultivating, cultivated 24 hours in 35 ℃, is minimum bactericidal concentration with the minimum dilution tube of no bacterial growth on the blood plate.3 Chloramphenicol Eye Drops are known broad spectrum antibiotic, and wide clinical application is not so do the extracorporeal bacteria inhibitor test of this medicine.
The external bacteriostasis of table 5 eye drop of the present invention (medicinal liquid dilution method in vitro)
Bacterial concentration minimum bactericidal concentration (mg/ml) minimum inhibitory concentration antibacterial self
10
210
310
210
3Contrast contrast bacterial classification gold Portugal bacterium 9.65+9.65 19.30+-ETEC+++++-epidermis grape pearl bacterium 9.65 9.65 9.65 9.65+-Streptococcus viridans 9.65 9.65 9.65 9.65+-Mo Lashi bacterium 9.65 9.65 9.65 9.65+-corynebacteria 19.30 38.6 9.65 9.65+-
Annotate: bacterial isolates is clinical separation strain, the no bacterial growth of " _ " expression,
"+" expression has bacterial growth.By table 4 as seen the result cultivates after 18 hours, and the antibacterial control tube all has bacterial growth.Eye drop of the present invention is to staphylococcus aureus, staphylococcus epidermidis, Streptococcus viridans, motor Salmonella, corynebacterium, the growth of 5 kinds of antibacterials of escherichia coli all has inhibitory action in various degree, from minimum inhibitory concentration and bacteriocidal concentration, remarkable to staphylococcus epidermidis, mora Salmonella, Streptococcus viridans effect, staphylococcus aureus, corynebacterium are taken second place.By above evidence, eye drop of the present invention has: 1. with eye drop successive administration of the present invention 3 days, the rabbit infective conjunctivitis is had the obvious treatment effect, large and small two dosage group effective percentage are respectively 100% and 80%; With 2 weeks of eye drop successive administration of the present invention, can reach 100% to the effective percentage of rabbit chronic conjunctivitis, large and small dosage group cure rate is respectively 81.2% and 63.6%, points out eye drop of the present invention that two kinds of conjunctivitis of rabbit are all had the obvious treatment effect.2. the heavy dose of group of eye drop of the present invention xylol induced mice dropsy of ear has significant inhibitory effect, and its suppression ratio can reach 62.8%.3. eye drop of the present invention all has in various degree inhibitory action to the growths of staphylococcus aureus, staphylococcus epidermidis, Streptococcus viridans, mora Salmonella, 5 kinds of antibacterials of corynebacterium, the most remarkable to staphylococcus epidermidis, grain Salmonella, Streptococcus viridans effect from minimum inhibitory concentration and bacteriocidal concentration, staphylococcus aureus, corynebacterium are taken second place.Eye drop of the present invention is obtained obvious curative effects to the treatment conjunctivitis, and this medicine of our evidence all has the obvious treatment effect to infectious, chronic conjunctivitis; And tangible pharmacological action is arranged at antiinflammatory, aspect antibacterial.
The specific embodiment: further specify the present invention by the following examples.
The above Six-element of embodiment 1 prescription Flos Lonicerae 10g Flos Buddlejae 10g Flos Chrysanthemi Indici 10g Herba Menthae 8g Margarita 0.5g Borneolum Syntheticum 0.1g method for making, get Flos Buddlejae, Flos Chrysanthemi Indici and Herba Menthae three flavor medicines, adding distil water 700ml, steam distillation, collect (armaticity) distillate 420ml, device is stored in addition; Flos Lonicerae decoct with water extract 3 times (each 0.5 hour, once add 16 times in water, two, respectively add 8 times in water for three times), decoction liquor is filtered, and filtrate merges, (the medicinal liquid: concentration medical material) that is concentrated into 1: 1, add ethanol and make and contain alcohol amount and reach 70%, the limit edged stirs, and leaves standstill 12 hours, filter, decompression recycling ethanol, adding distil water transfers to 10ml, and it is standby to sterilize; Margarita powder is broken into powder, adds an amount of furnishing pasty state of water, add 1.8 times of concentrated hydrochloric acid hydrolysis make molten, standing demix, filter, filtering residue reuse 15% hydrochloric acid reflux hydrolysis 24 hours, hydrolyzed solution filters, and merges hydrolyzed solution twice, heating in water bath drives acid, and reuse 10%NaOH transfers PH closely neutral, concentrates drying for standby; Borneolum Syntheticum adds the water grinding to be made molten, be sequentially added into the armaticity distillate of three medicines such as soluble pearl powder, Flos Lonicerae extractive solution, Flos Buddlejae then, and sodium chloride 9g, methyl parahydroxybenzoate, propyl ester (3: 1) mixture 0.4g, add water recently distilled at last to 1000ml, transfer PH to 5.5-6.5, mix homogeneously with 10%NaOH.In 4-10 ℃ of cold preservation 12 hours, filter, again with 0.2um microporous filter membrane fine straining, 121 ℃ of sterilizations of filtrate 15 minutes are distributed into 500 bottles of the collyrium of every bottle of 2ml under the aseptic condition, and packing promptly gets collyrium.
The above Six-element of embodiment 2 prescription Flos Lonicerae 10g Flos Buddlejae 10g Flos Chrysanthemi Indici 10g Herba Menthae 8g Margarita 0.5g Borneolum Syntheticum 0.1g method for makings, get Flos Buddlejae, Flos Chrysanthemi Indici and Herba Menthae three flavor medicines, adding distil water 700ml, steam distillation, collect (armaticity) distillate 420ml, device is stored in addition; Flos Lonicerae decoct with water extract 3 times (each 0.5 hour, once add 16 times in water, two, respectively add 8 times in water for three times), decoction liquor is filtered, and filtrate merges, (the medicinal liquid: concentration medical material) that is concentrated into 1: 1, add ethanol and make and contain alcohol amount and reach 70%, the limit edged stirs, and leaves standstill 12 hours, filter, decompression recycling ethanol, adding distil water transfers to 10ml, and it is standby to sterilize; Margarita powder is broken into powder, adds an amount of furnishing pasty state of water, add 1.8 times of concentrated hydrochloric acid hydrolysis make molten, standing demix, filter, filtering residue reuse 15% hydrochloric acid reflux hydrolysis 24 hours, hydrolyzed solution filters, and merges hydrolyzed solution twice, heating in water bath drives acid, and reuse 10%NaOH transfers PH closely neutral, concentrates drying for standby; Borneolum Syntheticum adds the water grinding to be made molten, be sequentially added into the armaticity distillate of three medicines such as soluble pearl powder, Flos Lonicerae extractive solution, Flos Buddlejae then, and sodium chloride 9g, methyl parahydroxybenzoate, propyl ester (3: 1) mixture 0.4g, add vaseline at last to 1000g, be distributed into 500 bottles of the spongaions of every bottle of 2g under the aseptic condition, the packing spongaion.
Embodiment 3 prescription Flos Lonicerae 10g Flos Buddlejae 10g Flos Chrysanthemi Indici 10g Herba Menthae 8g Margarita 0.5g Borneolum Syntheticum 0.1g preparation methoies are with embodiment 1, and the solution that is distributed into one bottle of 100ml applies the eye agent.
Claims (10)
1. a Chinese medicine preparation for the treatment of eye conjunctivitis is characterized in that, is made by the Chinese medicine of following weight proportion: Flos Lonicerae 50-150 part, Flos Buddlejae 50-150 part, Flos Chrysanthemi Indici 50-150 part, Herba Menthae 40-120 part, Margarita 2.5-7.5 part, Borneolum Syntheticum 0.5-1.5 part.
2. the preparation of claim 1, described proportioning is Flos Lonicerae 75-125 part, Flos Buddlejae 75-125 part, Flos Chrysanthemi Indici 75-125 part, Herba Menthae 60-100 part, Margarita 3-7 part, Borneolum Syntheticum 0.75-1.25 part.
3. the preparation of claim 1, described proportioning is 100 parts of Flos Loniceraes, 100 parts of Flos Buddlejaes, 100 parts of Flos Chrysanthemi Indicis, 80 parts of Herba Menthaes, 5 parts of Margaritas, 1 part of Borneolum Syntheticum.
4. the preparation of claim 1-3 is an ophthalmic preparation.
5. the preparation of claim 4 is solution, eye drop, the agent of deposited eye, eye unguentum, collyrium.
6. the preparation of claim 5 is eye drop.
7. the preparation method of the preparation of claim 6 is characterized in that, prepares according to the following step:
A. get Flos Buddlejae, Flos Chrysanthemi Indici and Herba Menthae three flavor medicines, add water, steam distillation is collected distillate;
B. the Flos Lonicerae extracting in water filters, and concentrates, and precipitate with ethanol filters, and concentrates, and adds water;
C. crushing pearl adds water furnishing pasty state, adds hydrochloric acid hydrolysis and makes moltenly, leaves standstill, filter, and filtering residue reuse hydrochloric acid hydrolysis, hydrolyzed solution filters, and merges hydrolyzed solution twice, and acid is driven in heating, transfers PH closely neutral, concentrates drying;
D. Borneolum Syntheticum adds water and makes moltenly, adds the Margarita powder of step c, the Flos Lonicerae extractive solution of step b, and the distillate of three medicines such as the Flos Buddlejae of step a, the medicine acceptable carrier adds water, filters sterilization.
8. the preparation method of claim 7 is characterized in that, the distillate among the step a is the armaticity distillate, and the hydrochloric acid among the step c is concentrated hydrochloric acid, and the medicine acceptable carrier in the steps d is a sodium chloride, the mixture of methyl hydroxybenzoate and nipasol.
9. the preparation method of claim 8, wherein the part by weight of the mixture of methyl hydroxybenzoate and nipasol is 3: 1.
10. the preparation of claim 1-6 is at a kind of cleaning heat and expelling wind of preparation, move back red antipruritic, yin nourishing makes eye bright, be used for eyelid and white fine blood vessel anfractuosity due to the wind heat visitor network, or blood vessel is indistinct, eye is scratchy dry and astringent, the mill pain is scorching hot, or ache the application in the medicine of (chronic conjunctivitis) of eye secretion, being unable to see for a long time, watching for a long time arranged.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021312508A CN1172711C (en) | 2002-09-19 | 2002-09-19 | Chinese medicine preparation for curing chronic conjunctivitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021312508A CN1172711C (en) | 2002-09-19 | 2002-09-19 | Chinese medicine preparation for curing chronic conjunctivitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1400004A true CN1400004A (en) | 2003-03-05 |
| CN1172711C CN1172711C (en) | 2004-10-27 |
Family
ID=4746610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021312508A Expired - Lifetime CN1172711C (en) | 2002-09-19 | 2002-09-19 | Chinese medicine preparation for curing chronic conjunctivitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1172711C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306430A (en) * | 2014-10-29 | 2015-01-28 | 广西信业生物技术有限公司 | Medical biological eye cold therapy dressing and preparation method thereof |
| CN106727957A (en) * | 2017-03-06 | 2017-05-31 | 安徽省双科药业有限公司 | A kind of gold treasure eye drops extracting technique of Chinese medicine |
| CN106902152A (en) * | 2017-03-06 | 2017-06-30 | 安徽省双科药业有限公司 | The eye drops and its production technology of a kind of anti-long visual fatigue |
| CN111544390A (en) * | 2020-05-21 | 2020-08-18 | 温州医科大学附属眼视光医院 | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method |
| CN115590919B (en) * | 2022-09-23 | 2024-02-13 | 合肥立方制药股份有限公司 | Application of butterflybush flower and extract thereof in preparation of artificial tears |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311842C (en) * | 2005-08-18 | 2007-04-25 | 北京市眼科研究所 | Medicine for treating chronic conjunctivitis |
-
2002
- 2002-09-19 CN CNB021312508A patent/CN1172711C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306430A (en) * | 2014-10-29 | 2015-01-28 | 广西信业生物技术有限公司 | Medical biological eye cold therapy dressing and preparation method thereof |
| CN106727957A (en) * | 2017-03-06 | 2017-05-31 | 安徽省双科药业有限公司 | A kind of gold treasure eye drops extracting technique of Chinese medicine |
| CN106902152A (en) * | 2017-03-06 | 2017-06-30 | 安徽省双科药业有限公司 | The eye drops and its production technology of a kind of anti-long visual fatigue |
| CN111544390A (en) * | 2020-05-21 | 2020-08-18 | 温州医科大学附属眼视光医院 | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method |
| CN111544390B (en) * | 2020-05-21 | 2022-04-15 | 温州医科大学附属眼视光医院 | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method |
| CN115590919B (en) * | 2022-09-23 | 2024-02-13 | 合肥立方制药股份有限公司 | Application of butterflybush flower and extract thereof in preparation of artificial tears |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1172711C (en) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139030B (en) | Oral Chinese herbal preparation for treating gingivitis and preparation method thereof | |
| CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
| CN105535107A (en) | Medicine composition for treating nasopharyngitis and preparing method of medicine composition | |
| CN104451927B (en) | A kind of Chinese medicine expelling parasite additive and application thereof | |
| CN102357196A (en) | External traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| CN1172711C (en) | Chinese medicine preparation for curing chronic conjunctivitis | |
| CN105012581A (en) | Fresh aloe antibacterial composite, application and preparing method of fresh aloe antibacterial composite | |
| CN107753554A (en) | A kind of prepared slices of Chinese crude drugs for eyeshield | |
| CN105613612A (en) | Agent for disinfecting intensive care unit and preparation method | |
| CN102988844A (en) | Gynaecological gel and extraction method thereof | |
| CN114306526B (en) | Compound broadleaf holly leaf traditional Chinese medicine extract and application thereof in preparing shower gel or hand sanitizer | |
| CN1201756C (en) | Medicinal atomization liquid for treating pharyngitis and its manufacturing process | |
| CN110882332B (en) | Antibacterial, anti-inflammatory and antiallergic nasal traditional Chinese medicine composition and preparation method and application thereof | |
| CN107753521A (en) | The application of a kind of Scolopendra extract and active component in wound repair field | |
| CN1283391A (en) | Extracted liquor for disinfection | |
| CN112826849A (en) | Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof | |
| CN1311842C (en) | Medicine for treating chronic conjunctivitis | |
| CN101869631B (en) | Toxicant elimination medicament for eyes | |
| CN105326954A (en) | Traditional Chinese medicine composition for treating blepharitis and preparing method thereof | |
| CN108686015A (en) | It is a kind of to treat dog skin disease Traditional Chinese medicine compound gel agent and its preparation method and application | |
| CN1259080C (en) | Bacteria and virus resisting and inflammation eliminating eye drop and its preparing process | |
| CN112263607B (en) | External traditional Chinese medicine composition for treating blepharitis marginalis and preparation method and application thereof | |
| CN1233360C (en) | Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity | |
| CN107519309A (en) | A kind of ophthalmic combined complete |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine preparation for curing chronic conjunctivitis Effective date of registration: 20180323 Granted publication date: 20041027 Pledgee: Bank of Communications Ltd. Anhui branch Pledgor: ANHUI SHUANGKE PHARMACEUTICAL CO.,LTD. Registration number: 2018340000084 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190628 Granted publication date: 20041027 Pledgee: Bank of Communications Ltd. Anhui branch Pledgor: ANHUI SHUANGKE PHARMACEUTICAL CO.,LTD. Registration number: 2018340000084 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine preparation for curing chronic conjunctivitis Effective date of registration: 20190705 Granted publication date: 20041027 Pledgee: Bank of Communications Ltd. Anhui branch Pledgor: ANHUI SHUANGKE PHARMACEUTICAL CO.,LTD. Registration number: 2019340000363 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201124 Address after: 100000 No. 1 East Lane, Beijing, Dongcheng District Patentee after: BEIJING TONGREN HOSPITAL, CAPITAL MEDICAL University Address before: 230088 No. 669 Changjiang West Road, Hefei, Anhui Patentee before: ANHUI SHUANGKE PHARMACEUTICAL Co.,Ltd. |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211221 Granted publication date: 20041027 Pledgee: Bank of Communications Ltd. Anhui branch Pledgor: ANHUI SHUANGKE PHARMACEUTICAL CO.,LTD. Registration number: 2019340000363 |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041027 |